Oxford BioTherapeutics
OBT is a clinical stage oncology company based in Oxford, UK and San Jose, USA.
OBT has a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies aimed at meeting needs in the field of cancer. OBT's IO discovery process provides insight into the cancer - immune cell synapse, and has identified several novel IO candidates for cancer therapy.
Latest Oxford BioTherapeutics News & Features
4 October 2022
14 October 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze